Overview

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
ioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
Phase:
Phase 1
Details
Lead Sponsor:
Respirent Pharmaceuticals Co Ltd.
Collaborator:
Becro Ltd.
Treatments:
Fluticasone
Fluticasone-Salmeterol Drug Combination
Salmeterol Xinafoate
Xhance